XNK Therapeutics’ Evencaleucel gains EMA recommendation
16 Jan 2024
Phase 2Gene TherapyCell TherapyImmunotherapy
Preview
Source: Pharmaceutical Technology
Supporting XNK Therapeutics’ work is a team that includes experts in NK cell research. Credit: Gorodenkoff/Shutterstock.com.
Preview
Source: Pharmaceutical Technology
XNK Therapeutics, a Sweden-based immunotherapy company, has received scientific recommendation from the European Medicines Agency’s (EMA) Committee for Advanced Therapies for its product Evencaleucel.
Evencaleucel is classified as a Somatic Cell Therapy Medicinal Product.
The classification places Evencaleucel within the category of Advanced Therapy Medicinal Products. The platform utilised by XNK to manufacture the product is designed to produce autologous natural killer (NK) cell-based drug candidates.
The candidates are developed to act on malignant ailments, both as mono and combination therapies.
The platform features a closed manufacturing system, which is pivotal for developing NK cell-based products.
The manufacturing process involves the careful expansion and activation of NK cells derived from the peripheral blood of cancer patients.
XNK has a pipeline that includes treatments for both haematological malignancies and solid tumours.
Evencaleucel is the company’s most advanced product and is currently undergoing Phase II clinical trials, evaluating the therapy along with isatuximab, a CD38 antibody, to treat multiple myeloma.
Another asset, XNK02, is in advanced preclinical studies in partnership with the MD Anderson Cancer CenterCancer Center to potentially treat acute myeloid leukaemia.
XNK03, aimed at treating bladder cancer, is in preclinical studies in partnership with the Karolinska University Hospital.
Supporting XNK Therapeutics’ innovative work is a team that includes experts in NK cell research.
The company also benefits from an approved in-house good manufacturing practice facility.
XNK Therapeutics chief medical officer Peter Hovstadius stated: “We are very pleased with EMA’s scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.